This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Merrimack Pharmaceuticals To Present Preclinical Research On Five Novel Cancer Therapies

CAMBRIDGE, Mass., April 2, 2013 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that research data on five novel experimental cancer therapies (MM-398, MM-121, MM-111, MM-302, and MM-141) will be presented at the 2013 American Association for Cancer Research (AACR) Annual Meeting, April 6-10, 2013 in Washington, DC.  Presentations will include preclinical data evaluating the potential of treatments to restore tumor drug sensitivity and delay resistance when used alone or in combination with other targeted treatments.  Data will be shared in late-breaking sessions, mini-symposia and poster sessions.

"We are excited about the advancements and research to be presented regarding several of the therapies in Merrimack's robust oncology pipeline," said Ulrik Nielsen, PhD, Co-Founder and Chief Scientific Officer, Merrimack Pharmaceuticals. "The research explores the potential of our novel medicines to inhibit signaling to prevent tumor growth and improve responsiveness to treatments, as well as the potential of our investigational nanotherapeutics to deliver chemotherapy directly to diseased cells to enhance activity and improve safety. These therapies are being studied across multiple cancers such as head and neck, lung, breast, gastric, pancreatic and melanoma."

Late-Breaking Poster
  • Session Title: Late-Breaking Research - Clinical Research 1 LB-79: Combined treatment with HER3 antibody MM-121/ SAR 256212 and EGFR antibody cetuximab in pre-clinical models of head and neck cancer Monday, April 8, 2013, 1:00 PM - 5:00 PMHall A-C, Poster Section 45

Mini-Symposium Presentations
  • Session Title: Preclinical and Molecular Endocrinology in Hormone-Responsive Cancers 1072: MM-121/ SAR256212, an anti-ErbB3 antibody, restores sensitivity to letrozole and delays the onset of resistance in an ER+ breast cancer model Sunday, April 7, 2013, 4:05 PM - 4:20 PMRoom 206, Washington Convention Center
  • Session Title: Novel Targeted Therapies 2 4633: MM-111, a bispecific HER2 and HER3 antibody, synergistically combines with trastuzumab and paclitaxel in preclinical models of gastric cancer Tuesday, April 9, 2013, 3:05 PM - 3:20 PMRoom 152, Washington Convention Center

Poster Sessions
  • Session Title: Experimental Combination Therapy 1 2077A: MM-141, a novel bispecific antibody co-inhibitor of IGF-1R and ErbB3, inhibits the proliferation of melanoma cells Monday, April 8, 2013, 1:00 PM -5:00 PMHall A-C, Poster Section 37
  • Session Title: Experimental Combination Therapy 2 3271: Tumor priming with cyclophosphamide increases delivery and activity of Her2-targeted liposomal doxorubicin (MM-302) in preclinical models of breast cancer Tuesday, April 9, 2013, 8:00 AM -12:00 PMHall A-C, Poster Section 37
  • Session Title: Novel Delivery Technologies 5622: The tumor microenvironment modulates the delivery and activation of liposomal encapsulated irinotecan, MM-398 Wednesday, April 10, 2013, 8:00 AM -12:00 PMHall A-C, Poster Section 41
  • Session Title: Antibody/Protein Therapeutics 5464: In-vitro studies of MM-121/ SAR 256212, an anti-ErbB-3 antibody, in combination with erlotinib in EGFR-wild-type NSCLC Wednesday, April 10, 2013, 8:00 AM -12:00 PMHall A-C, Poster Section 36

Sanofi and Merrimack entered into an exclusive, licensing and global collaboration agreement for MM-121 in 2009.

About Merrimack Pharmaceuticals, Inc.Merrimack Pharmaceuticals is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.

Forward-Looking StatementAny statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

SOURCE Merrimack Pharmaceuticals, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASDAQ 4,683.9190 -49.5780 -1.05%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs